Schizophrenia

US FDA approves Bristol Myers' Squibb drug for treating schizophrenia

Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last year

What makes Elon Musk's brain implant devices a double-edged sword

Neuralink's brain implant devices could cure paralysis and schizophrenia in humans, but concerns about privacy linger

Study finds young adulthood window best to treat schizophrenia, autism

Targeting and stimulating underperforming neurons in the dopamine system and increasing its activity in young adulthood could help treat neuropsychiatric disorders like schizophrenia and autism with long-lasting effects, according to a new study. In mice, researchers from the University of Rochester, US, found that stimulating the neuron cells providing dopamine to the frontal cortex strengthened the circuit and rescued structural deficiencies in the brain that cause long-term symptoms. In previous studies, the research team had found this specific arm of the dopamine system to be flexible in adolescents but not in adults. In this study, published in the journal eLife, they exploited this window for plasticity in the system as an opportunity for therapeutic intervention, effects of which could affect the brain circuitry into adulthood. Essential in higher cognitive processing and decision-making, dysfunction of the dopamine system has been found to often begin in young ...

Glenmark gets USFDA nod to market generic medication to treat schizophrenia

Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic product used to treat schizophrenia and in some cases to control severe nausea. The company has received nod from the US Food & Drug Administration (USFDA) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the Mumbai-based drug maker said in a statement. The company's product is the generic version of GlaxoSmithKline's Compazine tablets, it added. According to IQVIA sales data for the 12-month period ending January 2023, the Compazine tablets 5 mg and 10 mg achieved annual sales of around USD 26.9 million. Glenmark said its current portfolio consists of 182 products authorised for distribution in the US marketplace and 46 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA. PTI MSS.

Zydus Cadila gets USFDA approval to market generic schizophrenia drug

Cariprazine is an atypical antipsychotic medication used for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder.

Workplace support is a basic need for women fighting schizophrenia

For people with schizophrenia, the ability to pursue employment and be financially stable provides a measure of autonomy.

Dr Reddy's launches generic Ziprasidone Mesylate for injection in US

It's the therapeutic generic equivalent of Geodon Injections

Cadila Healthcare receives US FDA approval for schizophrenia drug

The product will be manufactured at Liva Pharma's manufacturing facility at Vadodara

Avatars can help schizophrenia patients control threatening voices

More research is needed to investigate the approach in other healthcare settings, so the therapy is not yet widely available

Schizophrenia patients may benefit from Avatar therapy

The therapy is also stronger than more general cognitive behavioural therapy and has shown clinically worthwhile benefits.

Schizophrenia risk mostly genetic: Study

80% of schizophrenia risk may be traced back to genes inherited from parents, suggests the study